Versant旗下Dayra公司携5000万美元与Biogen达成合作，致力于口服大环肽药物研发

VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already reeled in a partnership with Biogen.